• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于胰腺导管腺癌联合治疗的纳米载体：综述

Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

作者信息

Pontón Iris, Sánchez-García David

机构信息

Grup d'Enginyeria de Materials (GEMAT), Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017 Barcelona, Spain.

出版信息

Nanomaterials (Basel). 2025 Jul 22;15(15):1139. doi: 10.3390/nano15151139.

DOI:10.3390/nano15151139
PMID:40801679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12348418/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers worldwide, characterized by late diagnosis, aggressive progression, and poor response to conventional monotherapies. Combination therapies have emerged as a promising approach to overcome multidrug resistance (MDR), enhance efficacy, and target the complex tumor microenvironment (TME). Nanoparticle-based drug delivery systems (DDSs) have gained significant attention for their ability to co-deliver multiple agents with controlled release profiles. This review comprehensively examines nanoparticle-based platforms developed for PDAC combination therapies, focusing on small-molecule drugs. The systems discussed are drawn from studies published between 2005 and 2025.

摘要

胰腺导管腺癌（PDAC）仍然是全球最致命的癌症之一，其特点是诊断晚、进展迅速且对传统单一疗法反应不佳。联合疗法已成为一种有前景的方法，用于克服多药耐药性（MDR）、提高疗效并靶向复杂的肿瘤微环境（TME）。基于纳米颗粒的药物递送系统（DDS）因其能够以控释方式共同递送多种药物而备受关注。本综述全面研究了为PDAC联合疗法开发的基于纳米颗粒的平台，重点关注小分子药物。所讨论的系统来自2005年至2025年发表的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/31f381029567/nanomaterials-15-01139-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/e566c2a65e9a/nanomaterials-15-01139-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/b111dc9500c4/nanomaterials-15-01139-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/abf477872ae7/nanomaterials-15-01139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/464e5b5c14d6/nanomaterials-15-01139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/748ccc15eb13/nanomaterials-15-01139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/4d51f2e36b87/nanomaterials-15-01139-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/a7e14ff7b818/nanomaterials-15-01139-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/d5e2fd8b831a/nanomaterials-15-01139-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/207b33eae341/nanomaterials-15-01139-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/606b1a3a59a5/nanomaterials-15-01139-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/645abd38a2bc/nanomaterials-15-01139-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/d41b83c8be1a/nanomaterials-15-01139-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/31f381029567/nanomaterials-15-01139-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/e566c2a65e9a/nanomaterials-15-01139-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/b111dc9500c4/nanomaterials-15-01139-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/abf477872ae7/nanomaterials-15-01139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/464e5b5c14d6/nanomaterials-15-01139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/748ccc15eb13/nanomaterials-15-01139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/4d51f2e36b87/nanomaterials-15-01139-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/a7e14ff7b818/nanomaterials-15-01139-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/d5e2fd8b831a/nanomaterials-15-01139-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/207b33eae341/nanomaterials-15-01139-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/606b1a3a59a5/nanomaterials-15-01139-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/645abd38a2bc/nanomaterials-15-01139-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/d41b83c8be1a/nanomaterials-15-01139-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/600e/12348418/31f381029567/nanomaterials-15-01139-g011.jpg

相似文献

1
Nanocarriers for Combination Therapy in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.用于胰腺导管腺癌联合治疗的纳米载体：综述
Nanomaterials (Basel). 2025 Jul 22;15(15):1139. doi: 10.3390/nano15151139.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
6
Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma.空间生物学和类器官技术揭示了胰腺导管腺癌中一种潜在的抗治疗癌症干细胞群体。
bioRxiv. 2025 May 24:2025.05.22.655586. doi: 10.1101/2025.05.22.655586.
7
Theranostic nanoparticles for detection and treatment of pancreatic cancer.用于胰腺癌检测与治疗的诊疗纳米颗粒。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Jul-Aug;16(4):e1983. doi: 10.1002/wnan.1983.
8
Harnessing epigenetic inhibitors: A promising approach for overcoming challenges in pancreatic ductal adenocarcinoma treatment.利用表观遗传抑制剂：一种克服胰腺导管腺癌治疗挑战的有前景的方法。
Adv Drug Deliv Rev. 2025 Jun 16;224:115638. doi: 10.1016/j.addr.2025.115638.
9
Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges.胰腺癌患者来源的3D生物打印模型：迈向个性化治疗与克服肿瘤微环境挑战
Adv Drug Deliv Rev. 2025 Aug 7;225:115670. doi: 10.1016/j.addr.2025.115670.
10
Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment.改善胰腺腺癌的治疗结果：多模式治疗中免疫疗法的系统评价
Medicina (Kaunas). 2025 Jun 11;61(6):1076. doi: 10.3390/medicina61061076.

本文引用的文献

1
The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models.基质调节在靶向肿瘤细胞中的潜在应用：聚焦于胰腺癌和乳腺癌模型
Semin Cancer Biol. 2025 Aug;113:151-175. doi: 10.1016/j.semcancer.2025.05.003. Epub 2025 May 13.
2
Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC.针对胰腺癌肿瘤微环境的纳米医学策略的广泛综述
Int J Nanomedicine. 2025 Mar 17;20:3379-3406. doi: 10.2147/IJN.S504503. eCollection 2025.
3
A biomimetic dual-targeting nanomedicine for pancreatic cancer therapy.
一种用于胰腺癌治疗的仿生双靶点纳米药物。
J Mater Chem B. 2025 Mar 12;13(11):3716-3729. doi: 10.1039/d4tb02206h.
4
aPD-L1-facilitated theranostic and tumor microenvironment remodeling of pancreatic cancer via docetaxel-loaded phase-transformation nanoparticles triggered by low-intensity pulsed ultrasound.通过低强度脉冲超声触发的载多西他赛相变纳米颗粒，α程序性死亡受体配体1促进胰腺癌的诊疗及肿瘤微环境重塑
J Nanobiotechnology. 2025 Jan 28;23(1):48. doi: 10.1186/s12951-025-03105-7.
5
Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy.基于纳米颗粒的胰腺癌治疗策略的突破。
Biochem Pharmacol. 2025 Feb;232:116685. doi: 10.1016/j.bcp.2024.116685. Epub 2024 Nov 28.
6
Functionalized Nanomaterials In Pancreatic Cancer Theranostics And Molecular Imaging.功能化纳米材料在胰腺癌诊疗与分子成像中的应用
ChemistryOpen. 2025 Jan;14(1):e202400232. doi: 10.1002/open.202400232. Epub 2024 Oct 21.
7
Hybrid Nanoparticles of Extracellular Vesicles and Gemcitabine Prodrug-Loaded Liposomes with Enhanced Targeting Ability for Effective PDAC Treatment.细胞外囊泡与载吉西他滨前药脂质体的杂交纳米粒子，具有增强的靶向能力，可有效治疗 PDAC。
ACS Appl Bio Mater. 2024 Sep 16;7(9):6025-6033. doi: 10.1021/acsabm.4c00658. Epub 2024 Sep 4.
8
Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma.用于增强胰腺导管腺癌治疗反应的双载药肿瘤靶向聚合物纳米颗粒
Mater Today Bio. 2024 Aug 10;28:101199. doi: 10.1016/j.mtbio.2024.101199. eCollection 2024 Oct.
9
Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.吉西他滨脂质偶联物与 ONC201 联合治疗有效治疗原位胰腺肿瘤荷瘤小鼠。
ACS Appl Mater Interfaces. 2024 Jun 12;16(23):29686-29698. doi: 10.1021/acsami.4c02626. Epub 2024 May 30.
10
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.基于靶向纳米颗粒的胰腺癌诊断与治疗方案
Cancers (Basel). 2024 Apr 20;16(8):1589. doi: 10.3390/cancers16081589.